European Network for Hyperkinetic Disorders

Description of the organization

EUNETHYDIS is a network of scientists (animal and human research), clinicians and clinical researchers, cardiologists, pharmacologists and neuroscientists dedicated to the study and treatment of children with Attention Deficit Hyperactivity Disorder (ADHD) or Hyperkinesis. EUNETHYDIS has 40 full members and 120 junior members throughout the EU countries and has held an annual meeting for the last 20 years. Full members of EUNETHYDIS usually hold positions as chairs or heads of department and research institutions. They have all individually contributed both clinically and scientifically to the study of ADHD. Usually members of EUNETHYDIS have at least 20 international peer‐reviewed papers on or related to ADHD. EUNETHYDIS has been extremely influential in the care and management of ADHD in European countries and is recognized by institutions such as “The American Academy of Child and Adolescent Psychiatry”, “European Child and Adolescent psychiatry” and the American Psychiatric Association” as the key European organization on ADHD.


Previous experience

From the full members of EUNETHYDIS a “Guideline group” has been established which so far has published 3 papers on the diagnosis and treatment of ADHD, two general papers on quality of life in ADHD and is currently in the process of submitting a paper on Safety in ADHD “European Guidelines on managing adverse effects of medication for ADHD”. EUNETHYDIS has also been involved in various pharmacoepidemiological studies such as IMAGE and Biophyris.


Profile of staff members

Prof. Joseph Sergeant is a clinical neuropsychologist and the Chairman of EUNETHYDIS. He has published more than 150 articles on ADHD and has been on the Editorial Board of several journals in child psychiatry. He was also reviewer for high impact journals such as Neuroscience Reviews, Science and Nature. Prof Joe Sergeant has coordinated the EU subsidized project Biophyris (Contract NO ERBCHRXCT930303) involving six EU countries.

Prof. Taylor is an Emeritus Professor and has been the Head and Chair of Child Psychiatry at the Institute of Psychiatry in London. Due to his eminence in the field of ADHD he was Chairman of the NICE Committee on ADHD. He is also the first author on the “European Guidelines on diagnosis and treatment of ADHD”. Prof Eric Taylor is the editor of Journal Child Psychology and Psychiatry ADHD and is a reviewer for every journal in child psychiatry.


Main tasks in the project

In ADDUCE EUNETHYDIS will contribute to the management (WP1), i.e. evaluation of project progress and review of project results and dissemination (WP10) tasks. It will evaluate and advise on the scientific implications of the project and contribute to the planning of activities of individual work packages. It will make the infrastructure of the annual meetings available to the ADDUCE consortium.



The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!
In this newsletter, you can find some information on the final recruitment status of the 2 main studies:
- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use
Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before! 


Did you participate in the ADDUCE studies and are you curious about the latest news on the project?

Here you can find some information!

News for children, April 2015

News for adolescents, April 2015

News for parents, April 2015

The third ADDUCE Newsletter is available!

Read more about the ADDUCE studies:

- the prospective open-label methylphenidate pharmacovigilance study: recruitment status and spin-
off studies
- the long-term cardiovascular effects of methylphenidate use: study design and participation

and much more in the ADDUCE Newsletter 3, March 2015


The second ADDUCE Newsletter is available!
Read more about the 2 main ADDUCE studies:

  • WP3: prospective open-label methylphenidate
    pharmacovigilance study
  • WP8: long-term cardiovascular effects of methylphenidate use

and much more in the ADDUCE Newsletter 2, February 2013


16 - 19 OCTOBER 2016:

4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care

17 & 18 APRIL 2016:

ADDUCE Consortium meeting, London - UK

28 - 31 MAY 2015:

5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland

20 & 21 APRIL 2015:

ADDUCE Consortium meeting, Salina - Italy

21 - 24 MAY 2014:

3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders

19 & 20 MAY 2014:

ADDUCE Consortium meeting, Istanbul - Turkey

3 - 6 OCTOBER 2013:

23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders

6 - 9 JUNE 2013:            

4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy

4 & 5 JUNE 2013:

ADDUCE Consortium meeting, Milan - Italy

 6 & 7 JUNE 2012:            

ADDUCE Consortium meeting, Cagliari - Italy

23 MAY 2012:

2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain